Introduction: Iron deficiency anaemia (IDA) is commonly a result of colorectal cancer. Higher preoperative haemoglobin (Hb) is associated with an improved post-operative survival. The endpoint of normalising patients Hb is to reduce the need for perioperative blood transfusion which has oncological, safety and economic benefits.
INTRODUCTION
Iron deficiency anaemia (IDA) can be defined as a haemoglobin (Hb) of <110g/l in males, and <100g/l in females with microcytosis (Mean Cell Volume (MCV) <78fl and or ferritin <12ng/ml) [1] . Studies report up to 6.3% of all patients with IDA have colorectal cancer [2] , and 60% of patients with colorectal cancer have IDA [3] . This figure rises to around 80% of patients with right sided colon cancer having IDA Generally speaking, IDA is detrimental to colorectal cancer patients, in that a low Hb is linked with higher rates of peri-operative infections and an increased mortality in surgical patients [4] . The transfusion of blood in surgical patients can also be detrimental. Peri-operative blood transfusions are associated with an increased post-operative mortality [5] , increased infective complication rate [6] and an increased risk of cancer recurrence; thought to be due to angiogenic stimulation [7] or an immunosuppressive effects of transfused packed red cells [8, 9] There is also a financial cost to a blood transfusion with one unit of packed red cells costing £140 at our institution.
The Aim of this study is to compare the effect of oral iron and two forms of parenteral iron in raising the Hb and MCV of consecutive colorectal cancer patients with irondeficiency anemia, and their respective effect on blood transfusion requirement.
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We will also compare the overall costs of the three forms of iron supplementation, taking into account the need for blood transfusion.
METHODS
Out of 238 patients reviewed in our IDA clinic between September 2006 and April 2009, data was prospectively collected on 53 consecutive patients found to have colorectal cancer with IDA. They were initially treated pre-operatively with one of the following: Oral iron (Ferrous Sulphate 200mg twice daily), intravenous iron sucrose -100mg 3 times per week for a maximum of 12 cycles (Venofer® Syner-Med Ltd, UK) or intravenous iron dextran as a onceonly dose averaging 1100mg with a maximum of 20mg/kg. (CosmoFer® Vitaline Pharmaceuticals Ltd, UK.) The patients were not randomised into treatment groups in this study and were given the iron supplement available, depending on their diagnosis date and also pharmacy supply.
Each patients' pre-and post-iron treatment Hb's & MCV's were measured over time for the oral iron and the two forms of intravenous iron supplementation. The total Hb (g/l) and MCV (fl) rise over the course of treatment, the Hb rise per day (g/l/d) and the MCV rise per day (fl/d) were calculated and statistically analysed on an intention-to-treat basis, with two-tailed T-Tests.
The requirement for pre-operative transfusion was also noted and the overall cost (including blood transfusions) in each of the iron supplement groups, calculated. Data was again analysed with two-tailed T-Tests.
Both blood transfusions and intravenous iron therapy require patients to be admitted to hospital for a short time. Thus, we have included the time spent in the Medical Investigation Unit (MIU) for those patients receiving infusions at a locally calculated rate of £43.80/hr in our cost analysis. Again, two-tailed T-Tests were used.
RESULTS
Out of the 53 patients included in this study, 23 received oral iron, 11 received Venofer® and 19 received CosmoFer®. Each group has comparable demographics with respect to mean age, sex distribution, cancer stage and site ( Table 1) .
The majority of patients in this study had advanced cancers: 96% of all patients had T3/T4 lesions, with 59% having nodal disease and 19% having metastases ( Table 1) . 74% of patients in this study had a right-sided colonic cancer ( Table  1 ).
The total Hb rise over the course of treatment was significantly more with Venofer® and CosmoFer®, compared with oral iron (p=0.048, p=0.034). (Fig. 1) . There was no significant difference in total Hb rise between Venofer® and Cosmofer® (p=0.82). There were no significant differences between the iron supplements with regard total MCV rise.
The Hb rise per day (taking in account treatment course length - Table 2 ) was significantly more with Venofer® and CosmoFer®, compared with oral iron (p=0.002, p=0.001). (Fig. 2) . There was no difference in the Hb rise per day between Venofer® and CosmoFer® (p=0.16). Only CosmoFer® gave a significantly improved MCV rise/day over oral iron ( Fig. 1) , and was significantly more than Venofer® (p=0.04).
A clear difference is observed in the mean treatment course length; oral iron -52 days, Venofer® -4.5days, CosmoFer® -1day ( Table 2) . Although Venofer® and CosmoFer® cost significantly more than oral iron, the oral iron group required significantly more blood than the Venofer® (p=0.04) or CosmoFer® groups (p=0.01) ( Table 2 & Fig. 3) .
Although there was a trend for oral iron to cost more than either form of intravenous iron taking into account blood transfusion requirement; the difference in cost was not significant (Table 2 & Fig. 3) . There was also no significant difference in overall cost between the three treatment groups with the time needed in MIU added on (Table 2 & Fig. 3) .
DISCUSSION
Blood is certainly fast becoming our most precious resource, and especially so in surgery. Colorectal cancer patients in addition to many other solid tumors have long been reported to have reduced survival following blood transfusion. Chronic bleeding from the gastrointestinal tract results in iron deficiency, which ideally would be reversed by Fig. (2) . Mean Hb and MCV rise /day with different iron supplements. administration of iron rather than blood; as the risks of iron transfusion are dwarfed by the potential harm of receiving a blood transfusion.
Our study indicates that the end-point of pre-operative blood transfusion reduction in colorectal cancer patients is possible with the administration of pre-operative Venofer® or CosmoFer®, when compared with oral iron. Although the initial cost of both intravenous iron types are more than oral iron, this is balanced out by reduction in blood transfusion requirement in these groups resulting in no significant difference in cost overall.
There has been many studies indicating a benefit of intravenous iron in the treatment of anaemia associated with chronic kidney disease over oral iron [10] [11] [12] [13] . Several observational studies indicate significant rises in Hb and reductions in transfusion requirement in pre-operative patients after administration of intravenous iron sucrose in patients undergoing arthroplasty [14, 15] and hysterectomy [16] . A Spanish study including 84 patients reported a significant rise in haemoglobin of 1.6g/dl over 3-5 weeks preoperatively in anaemic unselected surgical patients receiving intravenous iron sucrose [17] .
In contrast, a recent randomised controlled trial comparing intravenous iron sucrose with placebo in the treatment of colorectal cancer-induced anaemia, reported no difference and no rise in pre-operative Hb and thus no benefit with iron sucrose in blood transfusion reduction [18] . In this study, 62 patients were randomised with 34 receiving 600mg of Venofer® in two divided doses of 300mg no less than 24hrs apart given a minimum of 15 days prior to surgery (average number of days or range was not stated in the article) [18] . Our dosing regimen for Venofer,® as recommended by the manufacturer, involves 100mg up to 3 times a week up to a maximum of 12 cycles. The average number of days from the first Venofer® administration to surgery in our study, was 27 days. These differences in methodology may account of the difference in results noted.
Little has been published using intravenous iron dextran in the treatment of pre-operative IDA. This may be due to early worries about high rates of anaphylaxis after administration [19] . Out of the 19 patients receiving CosmoFer® (Iron dexran) in our study, no one suffered an anaphylactic reaction.
In the perioperative period acute blood loss is possible and there are times that large tumors may bleed more than iron supplementation corrects the iron stores, in both of these examples blood transfusion is still perhaps inevitable.
As the majority of patients presenting with colorectal cancer are anaemic, it behoves the physician to be aware of the risks of blood and the potential alternatives including cosmoFer® and venofer®.
CONCLUSIONS

•
Blood transfusion reduction in colorectal cancerinduced IDA is possible by the increased Hemoglobin rise-rate of Venofer® or CosmoFer® over oral iron supplementation.
There is no increase in cost of parenteral over oral iron when taking into account blood transfusion requirement, in this cohort of patients.
Further studies on this topic may randomise between the three different iron supplementations used in our study with greater numbers of patients and possibly focus on cancer related outcomes of those patients who have avoided blood transfusion by prophylactically receiving iron. 
